Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [HEALTH]
2 clusters · 5 sources · 4 days · First seen · Last updated
Research into peptide treatments for diabetic retinopathy
Overview
Scientific research is advancing regarding peptide-based treatments to mitigate diabetic retinopathy. Initial studies conducted by researchers in Spain, involving the Complutense University of Madrid and the Fundación Jiménez Díaz, utilized a MiS1 peptide in mice. This peptide mimics the SOCS1 protein to regulate inflammatory signals, showing potential in reducing retinal thinning and stabilizing microglia cell structures in diabetic subjects.
Subsequent research by an international collaboration including institutions in Brazil and the United States identified a human molecule, the peptide Ac2-26. Derived from the anti-inflammatory protein Annexin A1, this peptide was tested on human retina models and “miniretinas.” The findings suggest that Ac2-26 can reduce inflammation and oxidative stress while protecting mitochondria, thereby preventing the premature death of nerve cells caused by high glucose levels.
Entities
Investigative Ophthalmology & Visual Science · Complutense University of Madrid · University of Colorado Anschutz · Fundación Jiménez Díaz · Federal University of São Paulo
Timeline
-
[HEALTH] 3 sourcesResearchers discover molecule that may protect vision from diabetes
Scientists from Brazil and the US have identified the peptide Ac2-26 as a potential tool to prevent vision loss caused by diabetic retinopathy by reducing retinal inflammation and oxidative stress.
-
[HEALTH] 2 sourcesResearchers test MiS1 peptide treatment for diabetic retinopathy in mice
A study led by the Complutense University of Madrid shows that a MiS1 peptide treatment may protect mice from retinal damage caused by type 2 diabetes.
Sources
diarioestrategia.cl · fatopaulista.com.br · leiaecocentral.com.br · planetaosasco.com · vozlibre.com